COVID-19: Vir Biotech to begin study of therapy candidate VIR-7831 in August
US: Vir Biotechnology Inc said on Tuesday it plans to start a mid-to-late stage trial of its Covid-19 drug candidate in August, as drugmakers across the globe rush to find treatments for the highly infectious virus.
The company's therapy candidate, VIR-7831, is a monoclonal antibody that binds itself to the SARS-CoV-2 live virus and neutralizes it.
Vir Biotech expects initial clinical data from the study to be available before the end of 2020.
There are currently no approved treatments or vaccine for Covid-19, which has infected more than 20 million and killed at least 736,577, according to a Reuters tally.
Gilead Sciences Inc on Monday filed an application with the US. Food and Drug Administration seeking full approval for remdesivir, its experimental Covid-19 drug.
Vir Biotech has two other Covid-19 antibody candidates in development, VIR-2703 and VIR-7832, and expects to start human clinical trials for both later this year.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.